Adverum Biotechnologies ( (ADVM) ) has issued an update.
Adverum Biotechnologies is dealing with a default situation involving its subtenants, Advanced Medical Partners, LLC, and Jaguar Gene Therapy, LLC, under the sublease for the NC Premises. Despite these challenges, Adverum Biotechnologies expects its financial resources, including cash, cash equivalents, and short-term investments, to sustain its operations into the second half of 2025.
More about Adverum Biotechnologies
YTD Price Performance: -3.96%
Average Trading Volume: 172,947
Technical Sentiment Signal: Buy
Current Market Cap: $95.9M
See more insights into ADVM stock on TipRanks’ Stock Analysis page.